Bharat Biotech and Bilthoven Biologicals B.V. Announce Collaboration to Produce and Supply Oral Polio Vaccines
A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.
Bharat Biotech, a global leader in vaccine and biotherapeutic innovation, and also the largest manufacturer of oral polio vaccines, and Bilthoven Biologicals B.V., (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in the Netherlands, announced a collaboration today, to further strengthen the production and supply security of Oral Polio Vaccines (OPV).
A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.
Read Also : APSEZ FY24 quarter results, net profit jumps 50%Through this collaboration, BBIL and BBio will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals.
Read Also : Federal Bank Wraps Up FY 24 With 24% Rise in Profit, highest NII, Maintains Robust Asset Quality
News Must Read
- WAPCOS became second Indian PSU in ADB Consulting
- Power Grid appoints Satyaprakash Dash as CS and Compliance Officer
- GE Power received orders from two state-owned PSUs and one JV entity
- SAIL-RITES JV bags Rs 818 crore wagon order from Indian Railways
- BHEL enters into Strategic Partnership Agreement with HIMA for Railway Signalling Business
- SJVN bids farewell to Smt. Geeta Kapur, CMD and Director (Personnel)
- Nilendu Kumar Singh assumes charge of CMD, CCL
- IndianOil Q4 Results: Profit plunges 52% YoY to Rs 4,838 crore
- REC Limited declares financial results, records highest ever annual net profit
- NHPC Limited to collaborate with Norwegian company